[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614699":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":21,"responsibleParty":39,"collaborators":10,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Women diagnosed with endometriosis, referred for treatment and\u002For follow-up to Reference Unit",null,"The study population consists of adult women (18 years or older) with a confirmed diagnosis of endometriosis based on transvaginal ultrasound showing clearly visible and measurable lesions (endometriomas or deep endometriotic lesions suitable for evaluation and follow-up), who are referred for a first consultation at the Endometriosis Reference Unit in Hospital Sant Pau.\n\nPatients must not have an expected indication for surgical intervention within the next two years, ensuring stable monitoring of disease progression and treatment effects.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Rocío Luna Guibourg, MD, PhD","CONTACT","+34935537041","rluna@santpau.cat",{"name":19,"role":15,"phone":16,"phoneExt":10,"email":20},"Aina Delgado-Morell, MD","adelgadom@santpau.cat",[22],{"facility":23,"status":10,"city":24,"state":25,"zip":10,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Hospital de la Santa Creu i Sant Pau","Barcelona","Catalonia","Spain","ES",{"type":29,"coordinates":30},"Point",[31,32],2.15899,41.38879,{"lat":32,"lon":31},[35],{"name":36,"role":15,"phone":37,"phoneExt":10,"email":38},"Institut de Recerca Sant Pau - IIB Sant Pau","+34935565617","uicec@santpau.cat",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Aina Delgado Morell","Co-Investigator","100614699","evolution-of-endometriosis-lesions-followed-by-ultrasound-and-quality-of-life-of-patients-factors-that-influence-disease-progression-in-a-prospective-cohort-100614699",false,"NCT07282990","Evolution of Endometriosis Lesions Followed by Ultrasound and Quality of Life of Patients: Factors That Influence Disease Progression in a Prospective Cohort","Evolution of Endometriosis Lesions and Quality of Life of Patients","Inclusion Criteria:\n\n1. Women with a confirmed diagnosis of endometriosis, based on ultrasound criteria. Diagnosis must be confirmed by transvaginal ultrasound with evidence of visible and measurable endometriotic lesions.\n2. Patients over 18 years of age. This criterion ensures that participants can provide informed consent and are of reproductive age, when the effects of endometriosis and its treatments are relevant to the study.\n3. A transvaginal ultrasound performed prior to enrollment showing endometriotic lesions (either endometriomas or deep lesions) with sufficient dimensions and characteristics for evaluation and follow-up.\n4. Patients who do not have an indication for scheduled surgery within the next two years. This ensures that the effects of treatment and the progression of the disease can be evaluated throughout the study follow-up period.\n5. Signed informed consent from the patient, indicating that she has understood the purpose of the study, the procedures involved, and the potential risks.\n\nExclusion Criteria:\n\n1. Patients with an indication for scheduled surgical treatment within the next two years. This includes patients requiring surgery for the removal of endometriotic lesions or to address related complications.\n2. Patients who are unwilling to undergo follow-up transvaginal ultrasound at scheduled visits (6 months, 1 year, 2 years). Ultrasound is essential for assessing disease progression and the impact of treatment.\n3. Patients who are unwilling to participate in the study after receiving all the information and providing their informed consent. Voluntary participation is crucial for the ethics of the study.\n4. Patients with intellectual disabilities or conditions that impair their understanding of the study terms and procedures, which could affect their ability to provide valid informed consent.\n5. Patients who are pregnant or breastfeeding at the time of enrollment. These conditions can influence the course of endometriosis and the response to treatment, and could complicate disease monitoring.\n6. Patients with serious concurrent illnesses or medical conditions that may interfere with the assessment of endometriosis, its progression, or the impact of treatment (e.g., severe chronic inflammatory diseases or cancer).\n7. Patients receiving concurrent treatments not permitted by the study protocol (e.g., experimental treatments for endometriosis or related conditions) that may interfere with the interpretation of the results.","FEMALE","18 Years",{"count":53,"type":54},100,"ESTIMATED","2 Years","OBSERVATIONAL","The goal of this prospective cohort study is to determine the factors that influence the progression of endometriosis and the quality of life of patients.\n\nThe main questions it aims to answer are:\n\n1. Is endometriosis a progressive disease?\n2. Is the progression of lesions visualized by ultrasound dependent on the medical treatment received?\n3. Does the clinical progression of patients correlate with the progression of lesions visualized on transvaginal ultrasound?\n4. Is ultrasound follow-up necessary for patients?\n5. Could clinical follow-up alone be safe for selected patients?\n\nResearchers will follow up a prospective cohort of 100 patients diagnosed with deep infiltrating endometriosis (DIE) +\u002F- endometriomas during 2 years, collecting data regarding their ultrasound exam and their symptoms and quality of life at stablished controls at recruitment, 6 months, 12 months and 24 months.",[59],"Endometriosis",[59,61,62,63,64],"Ultrasound","QoL","Progression","Ovarian reserve","NOT_YET_RECRUITING","2025-12-14",{"date":68,"type":69},"2025-12-19","ACTUAL",{"date":71,"type":54},"2025-12",{"date":73,"type":54},"2028-05",{"name":5,"class":6},1]